Journal of Clinical Immunology

, Volume 38, Issue 7, pp 757–766 | Cite as

Allogeneic Hematopoietic Cell Transplantation in Patients with Primary Immunodeficiencies in Korea: Eleven-Year Experience in a Single Center

  • Eun Sang Yi
  • Young Bae Choi
  • Na Hee Lee
  • Ji Won Lee
  • Ki Woong Sung
  • Hong Hoe Koo
  • Eun-Sook Kang
  • Yae-Jean Kim
  • Keon Hee YooEmail author
Original Article



We aimed to report our single-center experience of allogeneic hematopoietic cell transplantation (HCT), which has been the only curative option for certain patients with lethal primary immunodeficiencies (PIDs).


We summarized the results of HCT performed for patients with PIDs for 11 consecutive years from 2006 to 2016 at Samsung Medical Center, Seoul, Korea. Twenty-six patients with PIDs received HCT. Most had chronic granulomatous disease (42.3%), Wiskott Aldrich syndrome (15.4%), or severe combined immunodeficiency (11.5%).


Nine patients (34.6%) received HCT during the former half period and 17 patients (65.4%) during the latter half period. Donor types were categorized as: matched sibling donor (n = 5), unrelated donor (n = 17), and familial mismatched donor (FMMD) (n = 4). Unrelated HCT and FMMD transplantation were increasingly performed in the latter half period compared to the first (5 vs. 16, P = 0.034). Five patients experienced initial engraftment failure, but all of them were eventually engrafted after additional HCTs. The 3-year probability of overall survival was 72.0%. Seven patients (26.9%) died, and the causes of death were bacterial sepsis (n = 4), pneumonia (n = 1), chronic graft-versus-host disease (GVHD) (n = 1), and diffuse alveolar hemorrhage (n = 1). Two patients with bacterial sepsis and a patient with pneumonia also had chronic GVHD. Unrelated HCT and use of methotrexate were associated with poor outcome. Complete chimerism was attained in 85.0% at 1 year after HCT.


PID candidates have been increasingly identified for allogeneic HCT in Korea, and the majority of them could be cured by HCT. Establishment of a systematic registry of PID patients for HCT is needed.


Hematopoietic cell transplantation bone marrow transplantation primary immunodeficiency child 


Compliance with Ethical Standards

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Ethical Standards

The study was approved by the Institutional Review Board of Samsung Medical Center and performed in accordance with the principles of the Declaration of Helsinki. The informed consent was waived.

Supplementary material

10875_2018_542_MOESM1_ESM.docx (22 kb)
Supplementary Table S1 (DOCX 22 kb)


  1. 1.
    Picard C, Bobby Gaspar H, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee report on inborn errors of immunity. J Clin Immunol. 2018;38:96–128.CrossRefGoogle Scholar
  2. 2.
    Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol. 2015;35:696–726.CrossRefGoogle Scholar
  3. 3.
    Griffith LM, Cowan MJ, Notarangelo LD, Kohn DB, Puck JM, Shearer WT, et al. Primary Immune Deficiency Treatment Consortium (PIDTC) update. J Allergy Clin Immunol. 2016;138:375–85.CrossRefGoogle Scholar
  4. 4.
    Son S, Kang J, Kim JM, Sung S, Kim Y, Lee H, et al. The first newborn screening study of T-cell receptor excision circle and к-deleting recombination excision circle for severe combined immunodeficiency in Korea: a pilot study. Pediatr Infect Vaccine. 2017;24:134–40.CrossRefGoogle Scholar
  5. 5.
    Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet. 1968;2:1366–9.CrossRefGoogle Scholar
  6. 6.
    Bach FH, Albertini RJ, Joo P, Anderson JL, Bortin MM. Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet. 1968;2:1364–6.CrossRefGoogle Scholar
  7. 7.
    Antoine C, Muller S, Cant A, Cavazzana-Calvo M, Veys P, Vossen J, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99. Lancet. 2003;361:553–60.CrossRefGoogle Scholar
  8. 8.
    Gennery AR, Slatter MA, Grandin L, Taupin P, Cant AJ, Veys P, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol. 2010;126:602–10.e1–11.CrossRefGoogle Scholar
  9. 9.
    Pai SY, Cowan MJ. Stem cell transplantation for primary immunodeficiency diseases: the North American experience. Curr Opin Allergy Clin Immunol. 2014;14:521–6.CrossRefGoogle Scholar
  10. 10.
    Connelly JA. Hematopoietic stem cell transplant for a new primary immunodeficiency disorder: a voyage where no transplant physician has gone before. Biol Blood Marrow Transplant. 2017;23:863–4.CrossRefGoogle Scholar
  11. 11.
    Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.Google Scholar
  12. 12.
    Horwitz ME, Sullivan KM. Chronic graft-versus-host disease. Blood Rev. 2006;20:15–27.CrossRefGoogle Scholar
  13. 13.
    Baron F, Sandmaier BM. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia. 2006;20:1690–700.CrossRefGoogle Scholar
  14. 14.
    Rousso SZ, Shamriz O, Zilkha A, Braun J, Averbuch D, Or R, et al. Hematopoietic stem cell transplantations for primary immune deficiencies: 3 decades of experience from a tertiary medical center. J Pediatr Hematol Oncol. 2015;37:e295–300.CrossRefGoogle Scholar
  15. 15.
    Morio T, Atsuta Y, Tomizawa D, Nagamura-Inoue T, Kato K, Ariga T, et al. Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan. Br J Haematol. 2011;154:363–72.CrossRefGoogle Scholar
  16. 16.
    Filipovich AH, Stone JV, Tomany SC, Ireland M, Kollman C, Pelz CJ, et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood. 2001;97:1598–603.CrossRefGoogle Scholar
  17. 17.
    Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, et al. Transplantation outcomes for severe combined immunodeficiency, 2000–2009. N Engl J Med. 2014;371:434–46.CrossRefGoogle Scholar
  18. 18.
    Moratto D, Giliani S, Bonfim C, Mazzolari E, Fischer A, Ochs HD, et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980–2009: an international collaborative study. Blood. 2011;118:1675–84.CrossRefGoogle Scholar
  19. 19.
    Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729–35.CrossRefGoogle Scholar
  20. 20.
    Kharfan-Dabaja M, Mhaskar R, Reljic T, Pidala J, Perkins JB, Djulbegovic B, Kumar A. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2014;Cd010280.Google Scholar
  21. 21.
    Fernandes JF, Rocha V, Labopin M, Neven B, Moshous D, Gennery AR, et al. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood? Blood. 2012;119:2949–55.CrossRefGoogle Scholar
  22. 22.
    Chang TY, Jaing TH, Lee WI, Chen SH, Yang CP, Hung IJ. Single-institution experience of unrelated cord blood transplantation for primary immunodeficiency. J Pediatr Hematol Oncol. 2015;37:e191–3.CrossRefGoogle Scholar
  23. 23.
    Frangoul H, Wang L, Harrell FE Jr, Manes B, Calder C, Domm J. Unrelated umbilical cord blood transplantation in children with immune deficiency: results of a multicenter study. Bone Marrow Transplant. 2010;45:283–8.CrossRefGoogle Scholar
  24. 24.
    Park M, Lee YH, Kang HR, Lee JW, Kang HJ, Park KD, et al. Unrelated donor cord blood transplantation for non-malignant disorders in children and adolescents. Pediatr Transplant. 2014;18:221–9.CrossRefGoogle Scholar
  25. 25.
    Farhadfar N, Hogan WJ. Overview of the progress on haploidentical hematopoietic transplantation. World J Transplant. 2016;6:665–74.CrossRefGoogle Scholar
  26. 26.
    Dvorak CC, Hassan A, Slatter MA, Honig M, Lankester AC, Buckley RH, et al. Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency. J Allergy Clin Immunol. 2014;134:935–43 e15.CrossRefGoogle Scholar
  27. 27.
    Slatter MA, Gennery AR. Approaches to the removal of T-lymphocytes to minimize graft-versus-host disease in patients with primary immunodeficiencies who do not have a matched sibling donor. Curr Opin Allergy Clin Immunol. 2017;17:414–20.CrossRefGoogle Scholar
  28. 28.
    Rao K, Amrolia PJ, Jones A, Cale CM, Naik P, King D, et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood. 2005;105:879–85.CrossRefGoogle Scholar
  29. 29.
    Gungor T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2014;383:436–48.CrossRefGoogle Scholar
  30. 30.
    Ouachee-Chardin M, Elie C, de Saint Basile G, Le Deist F, Mahlaoui N, Picard C, et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. Pediatrics. 2006;117:e743–50.CrossRefGoogle Scholar
  31. 31.
    Slatter MA, Rao K, Abd Hamid IJ, Nademi Z, Chiesa R, Elfeky R, et al. Treosulfan and fludarabine conditioning for hematopoietic stem cell transplantation in children with primary immunodeficiency: UK experience. Biol Blood Marrow Transplant. 2018;24:529–36.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Eun Sang Yi
    • 1
    • 2
  • Young Bae Choi
    • 3
  • Na Hee Lee
    • 4
  • Ji Won Lee
    • 1
  • Ki Woong Sung
    • 1
  • Hong Hoe Koo
    • 1
  • Eun-Sook Kang
    • 5
  • Yae-Jean Kim
    • 6
  • Keon Hee Yoo
    • 1
    • 7
    • 8
    Email author
  1. 1.Division of Hematology and Oncology, Department of Pediatrics, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulSouth Korea
  2. 2.Department of PediatricsKorea University Guro Hospital, Korea University College of MedicineSeoulSouth Korea
  3. 3.Department of PediatricsChungbuk National University HospitalCheongjuSouth Korea
  4. 4.Department of Pediatrics, Cha Bundang Medical CentreCha UniversitySeongnamSouth Korea
  5. 5.Departments of laboratory Medicine & Genetics, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulSouth Korea
  6. 6.Division of Pediatric Infectious Diseases and Immunodeficiency, Department of Pediatrics, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulSouth Korea
  7. 7.Department of Health Science and TechnologySAIHST, Sungkyunkwan UniversitySeoulSouth Korea
  8. 8.Stem Cell & Regenerative Medicine InstituteSamsung Medical CenterSeoulSouth Korea

Personalised recommendations